Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Accumulated Expenses: 2017-2024

Historic Other Accumulated Expenses for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $2.7 million.

  • Aclaris Therapeutics' Other Accumulated Expenses rose 2.55% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 2.55%. This contributed to the annual value of $2.7 million for FY2024, which is 2.09% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Other Accumulated Expenses stood at $2.7 million for FY2024, which was up 2.09% from $2.6 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Other Accumulated Expenses ranged from a high of $2.7 million in FY2024 and a low of $217,000 during FY2022.
  • Over the past 3 years, Aclaris Therapeutics' median Other Accumulated Expenses value was $2.6 million (recorded in 2023), while the average stood at $1.8 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 87.49% in 2022, then surged by 1,111.06% in 2023.
  • Aclaris Therapeutics' Other Accumulated Expenses (Yearly) stood at $1.2 million in 2020, then skyrocketed by 47.70% to $1.7 million in 2021, then plummeted by 87.49% to $217,000 in 2022, then spiked by 1,111.06% to $2.6 million in 2023, then increased by 2.09% to $2.7 million in 2024.